Internal Medicine

Latest News


CME Content


The authors assert that “there remains a need to identify inexpensive and non-toxic therapies that target the underlying pathophysiology of autoimmune disorders” and that “Blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) pathway with low dose naltrexone (LDN) has been explored as one such therapy.”

As Peter Schnatz, DO, Reading Health System, completes his term as President of NAMS, he reflected on the initial goals he'd had before assuming his position. His primary initiative was to bring the best care they could to menopausal women. Schnatz said they'd been working really hard on reopening the conversation of the use and utilization of hormonal therapy.

Some have called Medtronics MiniMed 670G an "artificial pancreas." The device is not that. It still requires user intervention. That said, it requires less intervention than any of the devices that have come before it.